Stockscreener 앱 받기
737.67
2.09%
15.10
시간 외 거래:
737.75
0.08
+0.01%
Lilly Eli Co 주식(LLY)의 최신 뉴스
Eli Lilly Stock Faces Headwinds as CVS Caremark Favors Rival Wegovy for Weight-Loss Coverage | LLY Stock Price - paginasiete.bo
Pharmaceutical giant plans $5.9B Houston facility and more news to know - InnovationMap
Eli Lilly (LLY) Edges Higher in Early Trading: Key Metrics Investors Are Watching - Daily Chhattisgarh News
Lilly duets with 'Modern Family' star Eric Stonestreet for Mounjaro campaign - PR Week
Eli Lilly’s Strong Market Position and Innovative Drug Pipeline Justify Buy Rating with Target Price of USD 1,010 - TipRanks
Looking for a Blend of Growth and Dividend Stocks Amid Market Uncertainty? Consider This Low-Cost Vanguard ETF. - The Motley Fool
Eli Lilly (LLY) Bulls Eye $1,000 Stock Price Target as GLP-1 Alpha Bandwagon Rolls On - TipRanks
Lilly announces details of presentations at American Diabetes Association's (ADA) 85th Scientific Sessions - Eli Lilly and Company
Was Jim Cramer Right About Eli Lilly and Company (LLY)? - Insider Monkey
UBS maintains Eli Lilly stock with $1,050 target - Investing.com
Novo Is Losing Steam. Can It Oh, Oh, Oh, Obtain New Grounding? - Investor's Business Daily
Eli Lilly : A Breakout Biotech Powerhouse With Room to Run - MarketBeat
Eli Lilly (LLY) Gains Upper Hand in Weight-Loss Drug Market | LL - GuruFocus
Ochre Bio appoints ex- Eli Lilly and AstraZeneca VP as Non-Executive Director - Health Tech World
The weight loss war: Who is winning out between Novo-Nordisk and Eli Lilly? - Shares Magazine
‘Start a Position’ in Eli Lilly Stock (LLY), Says Jim Cramer - TipRanks
Is Eli Lilly And Company Stock Underperforming The Dow? - Barchart.com
Eli Lilly to Expand Pain Pipeline With $1B SiteOne Buyout Offer - TradingView
Lilly adds non-opioid painkiller to pipeline in $1B Siteone buyout - BioWorld MedTech
BMO reiterates Eli Lilly stock with $900 target on SiteOne deal - Investing.com
Eli Lilly vs. AstraZeneca: Which Pharma Powerhouse is the Better Buy? - The Globe and Mail
Lilly seeks to expand pain pipeline with $1B acquisition - dailyjournal.net
Lilly to acquire biotech developing pain drugs - statnews.com
Reports: Lilly eyes Houston for new $5.9B manufacturing facility - Indianapolis Business Journal
Lilly to acquire SiteOne Therapeutics to expand pain pipeline - World Pharmaceutical Frontiers
Eli Lilly to expand pain portfolio with SiteOne acquisition - Cleanroom Technology
Jim Cramer Notes Eli Lilly (LLY) Stock is at a “Decent Level to Start a Position” - Insider Monkey
Lilly snags Peninsula non-opioid pain drug company for up to $1 billionSan Francisco Business Times - The Business Journals
Eli Lilly Commits $1B to Get Drug That Could Rival Vertex’s New Non-Opioid Pain Med - MedCity News
Lilly's Acquisition Of SiteOne Aims For Opioid AlternativesEli Lilly (NYSE:LLY) - Benzinga
Eli Lilly Targets Pain Management Opportunity with SiteOne Therapeutics Acquisition - Insider Monkey
Eli Lilly Inks $1B Deal For Non-Opioid Pain-Drug Maker - Law360
Eli Lilly (LLY) Shows Strong Options Activity Amid Share Price Rise | LLY Stock News - GuruFocus
Lilly to buy pain drug developer SiteOne, challenging Vertex - BioPharma Dive
Eli Lilly to expand pain pipeline with $1bn SiteOne buyout - Pharmaceutical Technology
Eli Lilly to buy SiteOne for $1 billion with eye on non-opioid pain drug - Reuters
Eli Lilly’s Strategic Acquisition of SiteOne Therapeutics Bolsters Pain Management Portfolio and Supports Buy Rating - TipRanks
Eli Lilly (LLY) Expands into Pain Management Through Acquisition | LLY Stock News - GuruFocus
Eli Lilly (LLY) to Acquire SiteOne Therapeutics for $1 Billion - GuruFocus
Eli Lilly expands neuroscience pipeline with $1B SiteOne acquisition - Proactive financial news
Seven top pharmas posted revenue declines in Q1. The common thread? All are US firms - Fierce Pharma
Eli Lilly To Acquire SiteOne Therapeutics For Up To $1B To Advance Pain Management Pipeline: But Retail’s Unconvinced By Stocktwits - Investing.com India
Lilly to acquire SiteOne, enhancing non-opioid pain treatment options By Investing.com - Investing.com India
Lilly to acquire SiteOne, enhancing non-opioid pain treatment options - Investing.com Australia
Eli Lilly expands pain pipeline with acquisition of SiteOne Therapeutics By Investing.com - Investing.com Nigeria
Eli Lilly expands pain pipeline with acquisition of SiteOne Therapeutics - Investing.com
Eli Lilly (LLY) to Acquire SiteOne Therapeutics in $1 Billion De - GuruFocus
Eli Lilly’s SWOT analysis: stock poised for growth amid challenges - Investing.com
Eli Lilly to acquire privately held SiteOne - Yahoo
Eli Lilly & Co. (LLY) Acquires SiteOne Therapeutics - StreetInsider
Lilly to expand its pain pipeline with acquisition of SiteOne Therapeutics | Eli Lilly and Company - Eli Lilly and Company
Lilly Makes $1B Bet on Next-Generation Pain Treatment: Key Details of SiteOne Acquisition Revealed - Stock Titan
Investment Case For Eli Lilly Still Weak, Despite Novo Nordisk's Struggle (NYSE:LLY) - Seeking Alpha
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Lilly's blood drive breaks site record - reporter.net
Here's How the Pharmaceutical Import Tariffs Could Affect Eli Lilly - AOL.com
Eli Lilly (LLY) Considers New $5.9 Billion Plant in Houston, Texas - TipRanks
1.06%
자본화:
|
볼륨(24시간):